Omalizumab for severe atopic keratoconjunctivitis

A 35-year-old patient received omalizumab (300 mg twice a month) for 2 years for a severe atopic keratoconjunctivitis (AKC) in order to reduce the risk for steroid-induced keratitis. After 4 months, quality of life and ocular symptoms improved, and the use of oral steroids was strongly reduced. The...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Taillé, Camille, Doan, Serge, Neukirch, Catherine, Aubier, Michel
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2010
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3029882/
https://ncbi.nlm.nih.gov/pubmed/22791726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr.04.2010.2919
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller